KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cost of Revenue (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Cost of Revenue for 7 consecutive years, with $267.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 160.81% year-over-year to $267.7 million, compared with a TTM value of $677.2 million through Dec 2025, up 120.93%, and an annual FY2025 reading of $677.2 million, up 120.93% over the prior year.
  • Cost of Revenue was $267.7 million for Q4 2025 at Alnylam Pharmaceuticals, up from $197.2 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $267.7 million in Q4 2025 and bottomed at $23.0 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $75.4 million, with a median of $60.9 million recorded in 2024.
  • The sharpest move saw Cost of Revenue dropped 10.71% in 2024, then soared 160.81% in 2025.
  • Year by year, Cost of Revenue stood at $33.6 million in 2021, then soared by 37.27% to $46.2 million in 2022, then skyrocketed by 55.88% to $72.0 million in 2023, then surged by 42.62% to $102.6 million in 2024, then soared by 160.81% to $267.7 million in 2025.
  • Business Quant data shows Cost of Revenue for ALNY at $267.7 million in Q4 2025, $197.2 million in Q3 2025, and $142.0 million in Q2 2025.